XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 47.305

Change

+0.55 (+1.17)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.24 (-0.46%)

USD 128.40B
SXR8:F iShares Core S&P 500 UCITS ETF..

-2.20 (-0.39%)

USD 114.04B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.41 (-0.71%)

USD 108.41B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.07 (-0.46%)

USD 52.77B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 52.44B
VUSA:F Vanguard Funds Public Limited ..

-0.36 (-0.37%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

+0.03 (+0.44%)

USD 46.87B
0ZC:F Zscaler Inc

+3.55 (+1.37%)

USD 37.92B
BSND:F Danone SA

-0.10 (-0.68%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-0.04 (-0.03%)

USD 24.77B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.97% 11% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.97% 11% F 31% F
Trailing 12 Months  
Capital Gain -11.38% 12% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.38% 11% F 33% F
Trailing 5 Years  
Capital Gain 31.18% 43% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.18% 44% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain 9.74% 71% C- 66% D+
Dividend Return 9.74% 68% D+ 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.19% 59% D- 89% A-
Risk Adjusted Return 87.03% 84% B 88% B+
Market Capitalization 0.85B 70% C- 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike